Kedudukan dalam Saham
#26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Harga Saham
$0.12164306
Disegerakkan terakhir: 2024-11-11
Perubahan (1 hari)
-4.14%
Perubahan (1 tahun)
0.00%
Perdagangan PharmAust Limited (PAA)
Harga PAA dengan permodalan pasaran b
Modal pasaran bagi PharmAust Limited(PAA)
Modal Pasaran: $38.53M
Sehingga August 2026, PharmAust Limited mempunyai modal pasaran sebanyak $38.53M. Ini menjadikan PharmAust Limited syarikat ke-26700th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran PharmAust Limited dari 2001 hingga 2026
PAA berbanding dengan 5 teratas yang paling popular stocks
| Harga PAA |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.307T
|
+13,774,337.61%
|
|
|
|
|
$4.697T
|
+12,192,126.35%
|
|
|
|
|
$4.147T
|
+10,763,080.60%
|
|
|
|
|
$3.584T
|
+9,301,304.15%
|
|
|
|
|
$2.834T
|
+7,356,737.38%
|
